Cargando…
DNA damaging agents in ovarian cancer
Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agen...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573464/ https://www.ncbi.nlm.nih.gov/pubmed/33240444 http://dx.doi.org/10.1016/j.ejcsup.2020.06.001 |
_version_ | 1783597445378211840 |
---|---|
author | Barretina-Ginesta, Maria-Pilar |
author_facet | Barretina-Ginesta, Maria-Pilar |
author_sort | Barretina-Ginesta, Maria-Pilar |
collection | PubMed |
description | Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agents. Platinum is the most important agent for first-line and also for relapses, together with other drugs that can be given as monotherapy or along with platinum or other drugs. Lately, the emerging role of PARP inhibitors has changed the landscape of opportunities for patients with EOC. All these strategies will be reviewed in this article. |
format | Online Article Text |
id | pubmed-7573464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-75734642020-11-24 DNA damaging agents in ovarian cancer Barretina-Ginesta, Maria-Pilar EJC Suppl Article Epithelial ovarian cancer (EOC) is very sensitive to upfront chemotherapy. This condition is attributable to defects in the DNA damage repair system. Agents that damage DNA are the main drugs used for its treatment. Many EOC cells have DNA repair deficiencies that confer susceptibility to these agents. Platinum is the most important agent for first-line and also for relapses, together with other drugs that can be given as monotherapy or along with platinum or other drugs. Lately, the emerging role of PARP inhibitors has changed the landscape of opportunities for patients with EOC. All these strategies will be reviewed in this article. Elsevier 2020-08-22 /pmc/articles/PMC7573464/ /pubmed/33240444 http://dx.doi.org/10.1016/j.ejcsup.2020.06.001 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Barretina-Ginesta, Maria-Pilar DNA damaging agents in ovarian cancer |
title | DNA damaging agents in ovarian cancer |
title_full | DNA damaging agents in ovarian cancer |
title_fullStr | DNA damaging agents in ovarian cancer |
title_full_unstemmed | DNA damaging agents in ovarian cancer |
title_short | DNA damaging agents in ovarian cancer |
title_sort | dna damaging agents in ovarian cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573464/ https://www.ncbi.nlm.nih.gov/pubmed/33240444 http://dx.doi.org/10.1016/j.ejcsup.2020.06.001 |
work_keys_str_mv | AT barretinaginestamariapilar dnadamagingagentsinovariancancer |